BioWorld

Sep. 14, 2009

Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial

Plenty of Data and PDUFA Dates to Keep Biotech Busy This Fall

Discovery Labs to Meet with FDA to Propose Limited Surfaxin Trial

Discovery Laboratories Inc. has not given up on its Surfaxin drug candidate for respiratory distress syndrome, signaling Friday that it would propose a limited clinical trial to gain FDA approval. (BioWorld Today) Read More

Only 1 H1N1 Shot Needed, Data from Flu Study Shows

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...

BioWorld

Sep. 14, 2009

Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial

Plenty of Data and PDUFA Dates to Keep Biotech Busy This Fall

Other News To Note

Clinic Roundup

Financings Roundup

Discovery Labs to Meet with FDA to Propose Limited Surfaxin Trial

Only 1 H1N1 Shot Needed, Data from Flu Study Shows

Today's news in brief

To viral or not to viral: In vivo CAR T debates delivery tech

News in brief

KBN-2201 reverses key features of Alzheimer’s in mice

In vivo click ADCs could address tumor heterogeneity